These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Meningococcal vaccine: New product, new recommendations. Campos-Outcalt D J Fam Pract; 2005 Apr; 54(4):324-6. PubMed ID: 15833222 [TBL] [Abstract][Full Text] [Related]
45. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Jacobsson S; Hedberg ST; Mölling P; Unemo M; Comanducci M; Rappuoli R; Olcén P Vaccine; 2009 Mar; 27(10):1579-84. PubMed ID: 19162117 [TBL] [Abstract][Full Text] [Related]
46. Epidemiologic investigation and targeted vaccination initiative in response to an outbreak of meningococcal disease among illicit drug users in Brooklyn, New York. Weiss D; Stern EJ; Zimmerman C; Bregman B; Yeung A; Das D; Dentinger CM; Marx MA; Kornblum J; Lee L; Halse TA; Mayer LW; Hatcher CP; Theodore MJ; Schmink S; Harcourt BH; Zucker JR; Layton M; Clark TA; Clin Infect Dis; 2009 Apr; 48(7):894-901. PubMed ID: 19231975 [TBL] [Abstract][Full Text] [Related]
47. Meningococcal C conjugate vaccine: the experience in England and Wales. Campbell H; Borrow R; Salisbury D; Miller E Vaccine; 2009 Jun; 27 Suppl 2():B20-9. PubMed ID: 19477053 [TBL] [Abstract][Full Text] [Related]
48. Use of meningococcal vaccine in college freshmen reconsidered. Miller JL Am J Health Syst Pharm; 1999 Dec; 56(23):2372. PubMed ID: 10595797 [No Abstract] [Full Text] [Related]
54. Reverse vaccinology on the cusp. Jones D Nat Rev Drug Discov; 2012 Feb; 11(3):175-6. PubMed ID: 22322255 [No Abstract] [Full Text] [Related]
55. The effect of gamma globulin on acute respiratory illness in military recruits. Chin J; Stallones RA; Lennette EH Am J Epidemiol; 1967 Jul; 86(1):193-8. PubMed ID: 4951558 [No Abstract] [Full Text] [Related]
56. Meningococcal vaccine trials. Farrington P; Miller E Methods Mol Med; 2001; 66():371-93. PubMed ID: 21336769 [TBL] [Abstract][Full Text] [Related]
57. [Clinical trials of the new Norwegian vaccine against diseases caused by Meningococcus B]. Bjune G; Nøkleby H; Hareide B Tidsskr Nor Laegeforen; 1990 Feb; 110(5):614-7. PubMed ID: 2408194 [TBL] [Abstract][Full Text] [Related]
58. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci. Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907 [TBL] [Abstract][Full Text] [Related]
59. Design of clinical trials with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. Bjune G; Closs O; Frøholm LO; Grønnesby JK; Høiby EA; Nøkleby H NIPH Ann; 1991 Dec; 14(2):81-91; discussion 91-3. PubMed ID: 1812439 [TBL] [Abstract][Full Text] [Related]
60. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. Bjune G; Grønnesby JK; Høiby EA; Closs O; Nøkleby H NIPH Ann; 1991 Dec; 14(2):125-30; discussion 130-2. PubMed ID: 1812425 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]